미국의 정형외과용 바이오소재 시장 : 규모, 점유율, 동향 분석(2024-2030년) - MedSuite

Orthopedic Biomaterials Market Size, Share & Trends Analysis | United States | 2024-2030 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, Cellular Allografts, and 3 more

한글목차

미국의 정형외과용 바이오소재 시장 규모는 2023년 50억 달러가 넘을 것으로 예상됩니다. 이 시장은 연평균 5.3%의 CAGR로 성장하여 예측 기간 동안 72억 달러가 넘을 것으로 예상됩니다.

정형외과용 바이오소재 시장은 인구 통계학적 요인, 특히 고령화와 척추 골관절염(OA)의 증가에 크게 영향을 받고 있습니다. 척추 고정술의 증가는 OA 환자 증가와 밀접한 관련이 있으며, 이는 고령화와 밀접한 관련이 있으며, 2008년 베이비붐 세대의 첫 번째 세대가 정년퇴직을 시작한 이후 퇴행성 질환의 위험에 처한 인구가 늘어나면서 뼈 이식 등의 치료에 대한 수요가 증가하고 있습니다.

노인 인구가 계속 증가하고 비만율이 높아짐에 따라 퇴행성 질환의 유병률이 높아질 것으로 예상됩니다. 이러한 인구 통계학적 변화는 정형외과용 바이오소재 및 수복 시술에 대한 수요 증가를 강조하며 예측 기간 동안 시장 성장을 촉진할 것입니다.

이 보고서는 미국의 정형외과용 바이오소재 시장에 대해 조사했으며, 시장 개요와 함께 부문별 동향, COVID-19 영향 분석, 시장 촉진요인 및 저해요인, 경쟁사 시장 점유율 분석, 시장 진입 기업 개요 등의 정보를 전해드립니다.

목차

주요 요약

미국의 정형외과용 바이오소재 시장 개요

• 경쟁 분석
• 시장 동향
• 대상 시술
• 조사 대상 시술 코드
• 대상 시장
• 주요 보고서 업데이트
• 과거 버전
• 조사 방법

미국의 정형외과용 바이오소재 시장에 대한 COVID-19의 영향

미국의 정형외과용 바이오소재 시장 개요

• 소개
  • 골이식 대체품
  • 성장인자
  • 세포 동종이식
  • 세포 치료
  • 히알루론산(HA) 관절내 점성보충
  • 연골 수복
• 시장 개요와 동향 분석
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석
• 인수합병
• 기업 개요
  • Arthrex
  • Biocomposites
  • Bioventus
  • DePuy Synthes
  • Ferring Pharmaceuticals
  • Isto Biologics
  • Medtronic
  • MTF
  • NuVasive
  • Orthofix
  • Sanofi
  • Stryker
  • Terumo
  • Vericel
  • Zimmer Biomet
• SWOT 분석
• 소개
• 시술

정형외과용 골이식 대체품 시장

• 소개
• 시장 개요
• 시장 분석과 예측
• 대수 분석
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석

정형외과용 성장인자 시장

• 소개
• 시장 개요
• 시장 분석과 예측
• 대수 분석
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석

정형외과용 세포 이식 시장

• 소개
• 시장 개요
• 시장 분석과 예측
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석

정형외과용 세포 치료 시장

• 소개
• 시장 개요
• 시장 분석과 예측
• 대수 분석
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석

히알루론산 관절내 점성보충 시장

• 소개
• 시장 개요
• 시장 분석과 예측
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석

정형외과용 연골 수복 시장

• 소개
• 시장 개요
• 시장 분석과 예측
• 대수 분석
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석

ksm

영문 목차

영문목차

Product Description: In 2023, the U.S. orthopedic biomaterials market was valued at over $5.0 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching over $7.2 billion during the forecast period. The comprehensive report on the U.S. market for orthopedic biomaterials covers various segments, including bone graft substitutes (allografts, demineralized bone matrices (DBMs), xenografts, and synthetic bone grafts). The report also encompasses orthopedic growth factors, cellular allografts, orthopedic cell therapy (bone marrow aspirate concentrate and platelet-rich plasma), hyaluronic acid (HA) viscosupplementation (single-, two-, three-, and five-injection cycles), and orthopedic cartilage repair. The cartilage repair segment includes osteochondral allografts, meniscal allografts, autologous chondrocyte implantation, particulated juvenile allografts, and microfracture adjuncts.

DATA TYPES INCLUDED

Unit Sales, Average Selling Prices, Market Value & Growth Trends

Forecasts Until 2030, and Historical Data to 2020

Market Drivers & Limiters for Each Segment

Competitive Analysis with Market Shares for Each Segment

Recent Mergers & Acquisitions

COVID-19 Impact on the Digital Dentistry market

Disease Overviews and Demographic Information

Company Profiles, Product Portfolios and SWOT for Top Competitors

U.S. Orthopedic Biomaterials Market Insights

The orthopedic biomaterials market is heavily influenced by demographic trends, especially the aging population and the increasing incidence of osteoarthritis (OA) in the spine. The rise in spinal fusion procedures is closely linked to the growing number of OA cases, which correlate with advancing age. Since the first wave of baby boomers began retiring in 2008, the population at risk for degenerative diseases has expanded, increasing the demand for treatments such as bone grafts.

As the elderly population continues to grow and obesity rates remain high, the prevalence of degenerative diseases is expected to rise. This demographic shift underscores a heightened need for orthopedic biomaterials and restorative procedures, driving market growth throughout the forecast period.

U.S. Orthopedic Biomaterials Market Share Insights

In the U.S. orthopedic biomaterials market, three main competitors dominate: Medtronic, DePuy Synthes, and Stryker.

Medtronic maintained its leading position in 2023, particularly excelling in the bone graft substitute segment and the growth factor market with its successful INFUSE(TM) product.

DePuy Synthes held the second-largest market share, a position it has consistently maintained. The company demonstrated significant strength in the bone graft substitute and cellular allograft segments and also distributed the leading hyaluronic acid product. DePuy Synthes offers a demineralized bone matrix (DBM) product processed by the Musculoskeletal Transplant Foundation (MTF) and the DBX(R) product line, which complements its spinal hardware business. The DBX line includes an osteoinductive and osteoconductive bone graft substitute combined with DBM. Additionally, DePuy Synthes distributes Monovisc(R) and Orthovisc(R), single- and three-injection hyaluronic acid products manufactured by Anika Therapeutics.

Stryker secured the third-largest market share, supported by its extensive product portfolio in the bone graft substitute, growth factor, and cellular allograft markets. This position was largely achieved through strategic acquisitions of several previous competitors.

MARKET SEGMENTATION SUMMARY

U.S. Orthopedic Bone Graft Substitute Market - MedCore - Includes:

Material Type: Autograft, Allograft, Xenograft, Demineralized Bone Matrix, Synthetic.

U.S. Orthopedic Growth Factor Market- MedCore - Includes:

Indication Type: Cervical disc Degeneration, Tibial, Spinal, Ankle & Hindfoot.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cellular Allograft Market- MedCore - Includes:

Anatomy Type: Cervical Spine, Lumbar Spine, Foot & Ankle Allograft, Trauma Allograft.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cell Therapy Market- MedCore - Includes:

Material Type: Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate.

Patient Type: Pediatric/Neonatal, Adult.

U.S. Hyaluronic Acid Viscosupplementation Market - MedCore - Includes:

Injection Cycle Type: Single, Two, Three, Five-Injection.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cartilage Repair Market- MedCore - Includes:

Treatment Type: Microfracture, OATS, Osteochondral Allograft, Meniscal Allograft, Autologous Chondrocyte Implantation, Particulated Juvenile Allograft, Microfracture Adjunct.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

TABLE OF CONTENT

TABLE of CONTENTS

List of Figures

List of Charts

executive summary

U.S. Orthopedic Biomaterials Market Overview

Competitive Analysis

Market Trends

Market Developments

Procedures Included

Procedure Codes Investigated

Markets Included

Key Report Updates

Version History

research methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems and Perform Secondary Research
• Step 3: Preparation for Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast and Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review and Market Release
• Step 9: Customer Feedback and Market Monitoring

impact of covid-19 on THE U.S. Orthopedic Biomaterials Market

• 2.1 Introduction
• 2.2 Analysis By Market Segment
  • 2.2.1 Worst Case Scenario
  • 2.2.2 Base Case Scenario
  • 2.2.3 Best Case Scenario

Overview

• 3.1 Introduction

Product Assessment

• 4.1 Introduction
• 4.2 Product Portfolios
  • 4.2.1 Bone Graft Substitutes
  • 4.2.2 Growth Factors
    • 4.2.2.1.1 NELL-1 Bone Biologics
    • 4.2.2.1.2 INFUSE(R) by Medtronic
    • 4.2.2.1.3 OsteoAMP(R) by Bioventus Surgical
    • 4.2.2.1.4 OP-1(TM) by Stryker/Olympus Biotech (Delisted)
    • 4.2.2.1.5 The Osteogrow Study
    • 4.2.2.1.6 AUGMENT(R) Bone Graft
    • 4.2.2.1.7 Amplex(R) Osteobiologic Bone Graft Substitute
    • 4.2.2.1.8 i-Factor(TM) Peptide Bone Matrix
  • 4.2.3 Cellular Allografts
  • 4.2.4 Cell Therapy
    • 4.2.4.1 Platelet-Rich Plasma
    • 4.2.4.2 Bone Marrow Aspirate Concentrate
  • 4.2.5 Hyaluronic Acid Viscosupplementation (HAV)
  • 4.2.6 Cartilage Repair
• 4.3 Regulatory Issues and Recalls
  • 4.3.1 Bone Graft Substitute Market FDA Recalls
  • 4.3.2 Growth Factor Market FDA Recalls
• 4.4 Clinical Trials
  • 4.4.1 Bone Graft Substitute Market Clinical Trials
  • 4.4.2 Growth Factor Market Clinical Trials
  • 4.4.3 Cellular Allograft Market Clinical Trials
  • 4.4.4 Cell Therapy Market Clinical Trials
  • 4.4.5 Hyaluronic Acid Viscosupplementation Market
  • 4.4.6 Cartilage Repair Market Clinical Trials

U.S. Orthopedic Biomaterials Market Overview

• 5.1 Introduction
  • 5.1.1 Bone Graft Substitutes
  • 5.1.2 Growth Factors
  • 5.1.3 Cellular Allografts
  • 5.1.4 Cell Therapies
  • 5.1.5 Hyaluronic Acid (HA) Viscosupplementation
  • 5.1.6 Cartilage Repair
• 5.2 Market Overview & Trend Analysis
• 5.3 Drivers and Limiters
  • 5.3.1 Market Drivers
  • 5.3.2 Market Limiters
• 5.4 Competitive Market Share Analysis
• 5.5 Mergers and Acquisitions
• 5.6 Company Profiles
  • 5.6.1 Arthrex
  • 5.6.2 Biocomposites
  • 5.6.3 Bioventus
  • 5.6.4 DePuy Synthes
  • 5.6.5 Ferring Pharmaceuticals
  • 5.6.6 Isto Biologics
  • 5.6.7 Medtronic
  • 5.6.8 MTF
  • 5.6.9 NuVasive
  • 5.6.10 Orthofix
  • 5.6.11 Sanofi
  • 5.6.12 Stryker
  • 5.6.13 Terumo
  • 5.6.14 Vericel
  • 5.6.15 Zimmer Biomet
• 5.7 SWOT Analysis
  • 5.7.1 Arthrex
  • 5.7.2 Biocomposites
  • 5.7.3 Bioventus
  • 5.7.4 DePuy Synthes
  • 5.7.5 Ferring Pharmaceuticals
  • 5.7.6 Isto Biologics
  • 5.7.7 Medtronic
  • 5.7.8 MTF
  • 5.7.9 NuVasive
  • 5.7.10 Orthofix
  • 5.7.11 Sanofi
  • 5.7.12 Stryker
  • 5.7.13 Terumo
  • 5.7.14 Vericel
  • 5.7.15 Zimmer Biomet

Procedure Numbers

• 6.1 Introduction
• 6.2 Procedures
  • 6.2.1 Total Orthopedic Biomaterial Procedures by Segment
  • 6.2.2 Orthopedic Bone Grafting Procedures
    • 6.2.2.1 Orthopedic Bone Grafting Procedures by Material
    • 6.2.2.2 Orthopedic Bone Grafting Procedures by Indication
    • 6.2.2.2.1 Average Units Used per Procedure by Indication
    • 6.2.2.2.2 Autograft Procedures by Indication
    • 6.2.2.2.3 Allograft Procedures by Indication
    • 6.2.2.2.4 Xenograft Procedures by Indication
    • 6.2.2.2.5 DBM Procedures by Indication
    • 6.2.2.2.6 Synthetic Procedures by Indication
    • 6.2.2.3 Orthopedic Bone Grafting Procedures by Patient Type
    • 6.2.2.3.1 Allograft Procedures by Patient Type
    • 6.2.2.3.2 Xenograft Procedures by Patient Type
    • 6.2.2.3.3 DBM Procedures by Patient Type
    • 6.2.2.3.4 Synthetic Procedures by Patient Type
    • 6.2.2.4 Orthopedic Bone Grafting Procedures by Care Setting
  • 6.2.3 Orthopedic Growth Factor Procedures
    • 6.2.3.1 Orthopedic Growth Factor Procedures by Indication
    • 6.2.3.2 Orthopedic Growth Factor Procedures by Care Setting
  • 6.2.4 Orthopedic Cellular Allograft Procedures
    • 6.2.4.1 Cellular Allograft Procedures by Anatomy
    • 6.2.4.2 Cellular Allograft Procedures by Patient Type
    • 6.2.4.1 Cellular Allograft Procedures by Care Setting
  • 6.2.5 Orthopedic Cell Therapy Procedures
    • 6.2.5.1 Orthopedic Cell Therapy Procedures by Material Type
    • 6.2.5.2 Platelet-Rich Plasma Procedures by Indication
    • 6.2.5.3 Bone Marrow Aspirate Concentrate Procedures by Indication
    • 6.2.5.4 Orthopedic Cell Therapy Procedures by Patient Type
    • 6.2.5.1 Orthopedic Cell Therapy Procedures by Care Setting
  • 6.2.6 Hyaluronic Acid Viscosupplementation Procedures
    • 6.2.6.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle
    • 6.2.6.2 Hyaluronic Acid Viscosupplementation Procedures by Patient Type
    • 6.2.6.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting
  • 6.2.7 Orthopedic Cartilage Repair Procedures
    • 6.2.7.1 Orthopedic Cartilage Repair Procedures by Type
    • 6.2.7.2 Orthopedic Cartilage Repair Procedures by Patient Type
    • 6.2.7.3 Orthopedic Cartilage Repair Procedures by Care Setting

Orthopedic Bone Graft Substitute Market

• 7.1 Introduction
  • 7.1.1 Units per Procedure by Indication
• 7.2 Market Overview
  • 7.2.1 Orthopedic Bone Graft Substitute Market by Material
  • 7.2.2 Orthopedic Bone Graft Substitute Market by Indication
• 7.3 Market Analysis and Forecast
  • 7.3.1 Orthopedic Bone Graft Substitute Market
  • 7.3.2 Allograft Bone Graft Substitute Market
  • 7.3.3 Xenograft Bone Graft Substitute Market
  • 7.3.4 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
  • 7.3.5 Synthetic Bone Graft Substitute Market
    • 7.3.5.1 Synthetic Bone Graft Substitute Market by Generation Type
    • 7.3.5.1.1 Generation 1 Synthetic Bone Graft Substitute Market
    • 7.3.5.1.2 Generation 2 Synthetic Bone Graft Substitute Market
• 7.4 Unit Analysis
  • 7.4.1 Allograft Bone Graft Substitute Unit Analysis
    • 7.4.1.1 Allograft Bone Graft Substitute Units Sold by Indication
    • 7.4.1.2 Allograft Bone Graft Substitute Units Sold by Patient Type
    • 7.4.1.3 Allograft Bone Graft Substitute Units Sold by Setting
    • 7.4.1.4 Allograft Bone Graft Substitute Units Sold by Product Type
  • 7.4.2 Xenograft Bone Graft Substitute Unit Analysis
    • 7.4.2.1 Xenograft Bone Graft Substitute Units Sold by Indication
    • 7.4.2.2 Xenograft Bone Graft Substitute Units Sold by Patient Type
    • 7.4.2.3 Xenograft Bone Graft Substitute Units Sold by Setting
    • 7.4.2.4 Xenograft Bone Graft Substitute Units Sold by Product Type
  • 7.4.3 Demineralized Bone Matrix Allograft Bone Graft Substitute Unit Analysis
    • 7.4.3.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold Breakout by Carrier Status
    • 7.4.3.1.1 DBM with Carriers Market
    • 7.4.3.1.2 DBM without Carriers Market
    • 7.4.3.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication
    • 7.4.3.3 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Patient Type
    • 7.4.3.4 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Setting
    • 7.4.3.5 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Product Type
  • 7.4.4 Synthetic Bone Graft Substitute Unit Analysis
    • 7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication
    • 7.4.4.2 Synthetic Bone Graft Substitute Units Sold by Patient Type
    • 7.4.4.3 Synthetic Bone Graft Substitute Units Sold by Setting
    • 7.4.4.4 Synthetic Bone Graft Substitute Units Sold by Product Type
• 7.5 Drivers and Limiters
  • 7.5.1 Allograft Market
    • 7.5.1.1 Market Drivers
    • 7.5.1.2 Market Limiters
  • 7.5.2 Xenograft Market
    • 7.5.2.1 Market Drivers
    • 7.5.2.2 Market Limiters
  • 7.5.3 Demineralized Bone Matrix Bone Graft Substitute Market
    • 7.5.3.1 Market Drivers
    • 7.5.3.2 Market Limiters
  • 7.5.4 Synthetic Bone Graft Substitute Market
    • 7.5.4.1 Market Drivers
    • 7.5.4.2 Market Limiters
• 7.6 Competitive Market Share Analysis

Orthopedic Growth Factor Market

• 8.1 Introduction
  • 8.1.1 BMP-2 (Medtronic)
  • 8.1.2 PDGF-BB (Wright Medical)
  • 8.1.3 BMP-7 (Ember Therapeutics)
  • 8.1.4 P-15 Synthetic Small Peptide (Cerapedics)
• 8.2 Market Overview
• 8.3 Market Analysis and Forecast
  • 8.3.1 Orthopedic Growth Factor Market
  • 8.3.2 Cervical Disc Degeneration Orthopedic Growth Factor Market
  • 8.3.3 Tibial Fracture Orthopedic Growth Factor Market
  • 8.3.4 Spine Orthopedic Growth Factor Market
  • 8.3.5 Ankle and Hindfoot Fusion Orthopedic Growth Factor Market
• 8.4 Unit Analysis
  • 8.4.1 Cervical Disc Degeneration Growth Factor Units Sold by Setting
  • 8.4.2 Tibial Fracture Growth Factor Units Sold by Setting
  • 8.4.3 Spine Growth Factor Units Sold by Setting
  • 8.4.4 Ankle and Hindfoot Fusion Growth Factor Units Sold by Setting
• 8.5 Drivers and Limiters
  • 8.5.1 Market Drivers
  • 8.5.2 Market Limiters
• 8.6 Competitive Market Share Analysis

orthopedic Cellular Allograft Market

• 9.1 Introduction
  • 9.1.1 Lineage
    • 9.1.1.1 Human Embryonic Stem Cells (hESC)
    • 9.1.1.2 Mesenchymal Stem Cells (MSC)
  • 9.1.2 Other Therapeutic Applications
• 9.2 Market Overview
• 9.3 Market Analysis and Forecast
  • 9.3.1 Orthopedic Cellular Allograft Market
  • 9.3.2 Cervical Spine Orthopedic Cellular Allograft Market
  • 9.3.3 Lumbar Spine Orthopedic Cellular Allograft Market
  • 9.3.4 Foot and Ankle Cellular Allograft Market
  • 9.3.5 Trauma Cellular Allograft Market
• 9.4 Drivers and Limiters
  • 9.4.1 Market Drivers
  • 9.4.2 Market Limiters
• 9.5 Competitive Market Share Analysis

Orthopedic Cell Therapy Market

• 10.1 Introduction
• 10.2 Market Overview
• 10.3 Market Analysis and Forecast
  • 10.3.1 Platelet-Rich Plasma Market
  • 10.3.2 Bone Marrow Aspirate Concentrate Market
• 10.4 Unit Analysis
  • 10.4.1 Platelet-Rich Plasma Units Sold by Indication Anatomy
  • 10.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication Anatomy
• 10.5 Drivers and Limiters
  • 10.5.1 Market Drivers
  • 10.5.2 Market Limiters
• 10.6 Competitive Market Share Analysis

Hyaluronic Acid Viscosupplementation Market

• 11.1 Introduction
  • 11.1.1 Benefits of Viscosupplementation
  • 11.1.2 Synovial Fluid
  • 11.1.3 Product Types
    • 11.1.3.1 Single-Injection Products
    • 11.1.3.2 Two-Injection Cycle Products
    • 11.1.3.3 Three-Injection Cycle Products
    • 11.1.3.4 Three-/Five-Injection Cycle Products
  • 11.1.4 Reimbursement
• 11.2 Market Overview
• 11.3 Market Analysis and Forecast
  • 11.3.1 Hyaluronic Acid Viscosupplementation Market
  • 11.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
  • 11.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market
  • 11.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market
  • 11.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market
• 11.4 Drivers and Limiters
  • 11.4.1 Market Drivers
  • 11.4.2 Market Limiters
• 11.5 Competitive Market Share Analysis

Orthopedic Cartilage Repair Market

• 12.1 Introduction
  • 12.1.1 Anatomy
  • 12.1.2 Methods for Cartilage Repair
    • 12.1.2.1 Microfracture
    • 12.1.2.2 Microfracture Adjunct
    • 12.1.2.3 Osteoarticular Autograft Transfer System
    • 12.1.2.4 Particulated Juvenile Allograft
    • 12.1.2.5 Osteochondral Allograft Transfer
    • 12.1.2.6 Autologous Chondrocyte Implantation
    • 12.1.2.7 Meniscal Allograft Transplantation
• 12.2 Market Overview
• 12.3 Market Analysis and Forecast
  • 12.3.1 Osteochondral Allograft Market
  • 12.3.2 Meniscal Allograft Market
  • 12.3.3 Autologous Chondrocyte Implantation Market
  • 12.3.4 Particulated Juvenile Allograft Market
  • 12.3.5 Microfracture Adjunct Market
• 12.4 Unit Analysis
  • 12.4.1 Osteochondral Allograft Cartilage Repair Units Sold by Patient Type
  • 12.4.2 Meniscal Allograft Cartilage Repair Units Sold by Patient Type
  • 12.4.3 Autologous Chondrocyte Implantation Cartilage Repair Units Sold by Patient Type
  • 12.4.4 Particulated Juvenile Cartilage Repair Units Sold by Patient Type
  • 12.4.5 Microfracture Adjunct Cartilage Repair Units Sold by Patient Type
• 12.5 Drivers and Limiters
  • 12.5.1 Market Drivers
  • 12.5.2 Market Limiters
• 12.6 Competitive Market Share Analysis

Abbreviations

관련자료